| Literature DB >> 32447387 |
Ye-Cheng Zhou1,2,3, Shu-Mei He4,5, Zi-Lu Wen1, Jun-Wei Zhao6, Yan-Zheng Song1, Ying Zhang7, Shu-Lin Zhang1,3.
Abstract
Rapid and accurate diagnosis of multidrug-resistant tuberculosis (MDR-TB) is important for timely and appropriate therapy. In this study, a rapid and easy-to-perform molecular test that integrated polymerase chain reaction (PCR) amplification and a specific 96-well microplate hybridization assay, called PCR-ELISA (enzyme-linked immunosorbent assay), were developed for detection of mutations in rpoB, katG, and inhA genes responsible for rifampin (RIF) and isoniazid (INH) resistance and prediction of drug susceptibility in Mycobacterium tuberculosis clinical isolates. We evaluated the utility of this method by using 32 multidrug-resistent (MDR) isolates and 22 susceptible isolates; subsequently, we compared the results with data obtained by conventional drug susceptibility testing and DNA sequencing. The sensitivity and specificity of the PCR-ELISA test were 93.7% and 100% for detecting RIF resistance, and 87.5% and 100% for detecting INH resistance, respectively. These results were comparable to those yielded by commercially available molecular tests such as the GenoType MTBDRplus assay. Based on the aforementioned results, we conclude that the PCR-ELISA microplate hybridization assay is a rapid, inexpensive, convenient, and reliable test that will be useful for rapid diagnosis of MDR-TB, for improved clinical care. © American Society for Clinical Pathology 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.Entities:
Keywords: zzm321990 Mycobacterium tuberculosiszzm321990 ; PCR; drug resistance; hybridization assay; isoniazid; rifampicin
Mesh:
Year: 2020 PMID: 32447387 DOI: 10.1093/labmed/lmaa016
Source DB: PubMed Journal: Lab Med ISSN: 0007-5027